Skip to main content
Journal ArticleOPEN ACCESS

Clinical efficacy and safety of anti-PD-1/PD-L1 treatments in non-small cell lung cancer (NSCLC)

Artificial Cells, Nanomedicine and Biotechnology (2019) 47(1) 4194-4201
DOI: 10.1080/21691401.2019.1687499
7Citations
Citations of this article
26Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Aims: The present study was performed to investigate the efficacy and safety of anti-programmed death-1 (PD-1)/programmed death-ligand-1 (PD-L1) treatments in non-small cell lung cancer (NSCLC). Methods: The potential articles were searched from Pubmed and Embase. The end points included overall survival (OS), progression-free survival (PFS), objective response rate (ORR) and adverse events. p

Author supplied keywords

Cite

CITATION STYLE

APA

Zeng, T., Qin, Q., Bian, Z., & Li, J. (2019). Clinical efficacy and safety of anti-PD-1/PD-L1 treatments in non-small cell lung cancer (NSCLC). Artificial Cells, Nanomedicine and Biotechnology, 47(1), 4194–4201. https://doi.org/10.1080/21691401.2019.1687499

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free